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In the previous issue of *Breast Cancer Research*, Lim and colleagues separated the various cellular components of the mouse mammary gland - including mammary stem cells (MaSCs), luminal progenitor cells, and differentiated luminal cells - to compare normal mouse and human mammary epithelial cells and various mouse tumors at the transcriptome level \[[@B1]\]. These results shed light on the remarkable conservation of signaling pathways in mouse and human breast cells, and potentially predict which cells may be the cell of origin for different breast tumors. Identification of the pathways in the various cellular components, such as IL-8 signaling in the MaSC, paves the way to develop eradication strategies against these cells.

While the human and mouse breast tissues exhibit distinct structural differences, there is increasing evidence of similar cellular hierarchies in both species \[[@B2]\]. In recent years, numerous groups have reported the isolation and functional characterization of these cells from mouse and human breast tissue \[[@B3]-[@B5]\]. From these studies, it was shown that the MaSC lies at the apex and can differentiate to produce luminal or myoepithelial progenitor cells, which generate the mature ductal alveolar, and myoepithelial cells that comprise the ductal epithelial network. Similarly, we previously identified a rare cell population - termed cancer stem cells (CSCs) - in human breast tumors able to initiate and sustain tumorigenesis in immunocompromised NOD/SCID mice, indicating that a similar hierarchy exists in breast cancer \[[@B6]\].

Human breast cancer is a histologically, molecularly, and epidemiologically heterogeneous disease. There are six molecular subtypes based on gene expression analysis, which include normal breast-like, luminal A, luminal B, basal-like, claudin-low, and *HER2/ERBB2*overexpressing \[[@B7]-[@B9]\]. The molecular heterogeneity among breast cancers has been suggested to result from different targets of transformation (that is, cell of origin), which has direct implications for prevention, detection, and treatment of breast cancer. Indeed, Lim and colleagues previously reported an increase in luminal progenitor cells in women heterozygous for *BRCA1*mutations and demonstrated that these tumors were more similar at the transcriptome level to luminal progenitors than the MaSC-enriched population \[[@B5]\]. Additionally, the human MaSC-enriched fraction was more similar to claudin-low and normal breast-like tumors, suggesting the distinct molecular subtypes may derive from distinct cell types.

Building upon these studies, Lim and colleagues isolated by flow cytometry the analogous mouse mammary cell subtypes (MaSC-enriched, luminal progenitor, mature luminal, and stromal) using CD24, CD29, and CD61 expression, and defined gene expression profiles of these populations using microarray analysis \[[@B1]\]. Remarkably, comparison with previous expression profiling of human mammary epithelial cell subtypes showed conservation of gene expression patterns between the two species. Perhaps reflecting the inability to further fractionate the MaSC-enriched fraction, which includes basal progenitor and mature myoepithelial cells due to common cell-surface molecules, it is not surprising that this fraction had the largest number of conserved genes (489 upregulated and 428 downregulated).

As with any gene expression study, the ability to tease apart the signaling pathways represents a potential roadblock. Lim and colleagues used Ingenuity Pathway Analysis, a manually collated database, to identify conserved networks in the MaSC-enriched, luminal progenitor, and mature luminal subpopulations. Prominent within the MaSC-enriched signature were ephrin, integrin, IL-8, *p53*, and *Wnt*signaling pathways. Additionally, some epithelial-mesenchymal transition (EMT) markers (*Slug*, *Twist2*, *vimentin*) were identified. The acquisition of an EMT phenotype has been suggested to contribute to metastasis \[[@B10]\], and the observation that cells undergoing EMT were enriched for and had characteristics of breast CSCs was recently harnessed to identify potential anti-CSC agents \[[@B11]\]. Whether breast tumor cells expressing these genes acquired basal cell characteristics rather than EMT, however, remains to be determined.

To extend upon their previous studies comparing normal human cell subpopulations with the six molecular subtypes of breast cancer \[[@B5]\], Lim and colleagues compared the four mouse cell subsets with six genetically engineered mouse mammary tumor models: *MMTVWnt1*, *MMTV-Neu*, *MMTV-PyMT*, *WAP-Myc*, *WAPInt3*(*Notch-1*), and *p53-null*\[[@B1]\]. The gene signature from the MaSC-enriched subset was enriched in *MMTV-Wnt1*and *p53-null*tumors, whereas the luminal progenitor signature was higher in *MMTV-Neu*and *MMTV-PyMT*tumors and the mature luminal signature was most similar to the *MMTV-Myc*tumors. While these expression data are suggestive of the cell of origin for the various breast cancers, they may reflect an expansion of a particular cell type during tumor progression. Indeed, Cho and colleagues recently reported that *MMTV-Wnt1*mouse breast tumors contain Thy1^+^CD24^+^tumorinitiating cells. Microarray analysis of this population defined a gene expression profile of which the orthologs predicted survival in breast cancer patients \[[@B12]\]. Further studies using overexpression of these oncogenes in the various purified breast epithelial cell types may help identify the true cell of origin for breast cancer similar to studies carried out in murine leukemias with hematopoietic stem and progenitor cells \[[@B13],[@B14]\].

In summary, the results of Lim and colleagues highlight the development of new approaches to understand the role of various cell types in breast tumor initiation and demonstrate that mouse tumor models may be useful in screening new breast cancer therapeutics. Moreover, the conservation of signaling pathways between mouse and human may facilitate the identification of valuable targets for therapeutic development. Using similar gene expression studies of breast cancer cells, we identified IL-8 signaling in breast CSCs and showed that the CXCR1 (IL-8 receptor) inhibitor repertaxin is able to target breast cancer stem cells \[[@B15]\]. It remains to be determined whether other signaling pathways identified by Lim and colleagues in MaSCs, luminal progenitor cells (that is, CXCR4 or KIT), or mature luminal cells can be successfully targeted in breast cancer.
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